

Letter to the Editor

The Role of Interleukin-23/Interleukin-17 Axis in Coexisting Anti-glomerular Basement Membrane Disease and Lupus Nephritis

To the Editor,

We read with great interest the contribution by Yadla et al¹ entitled, "An unusual association of anti-GBM diseases and lupus nephritis presenting as pulmonary renal syndrome," published in your esteemed journal. They reported an unusual case of coexisting lupus nephritis (LN) and anti-glomerular basement membrane (anti-GBM) disease and suggested three plausible pathogeneses of the association between the two diseases: Interstitial pneumonitis due to LN and secondary production of anti-GBM antibody, downstream molecular pathways including complement- and FcR-dependent activation of resident renal cells, and kallikrein. We would like to add another possible pathomechanism in view of immunopathology.

According to an *in vitro* experiment by Zhang et al,² interleukin (IL)-23-induced nephritis by lymph node cells from lupus-prone mice and the expression of IL-17 and IL-23 receptors in lymphocytes increased as the disease progressively worsened. *Ex vivo* induction of IL-17 by IL-23 from co-stimulated lymphocytes was significantly higher in systemic lupus erythematosus patients than controls ($P < 0.05$).³ In another animal study, IL-23R-deficient lupus-prone C57BL/6-lpr/lpr mice showed decreased number of CD3(+)CD4(-)CD8(-) double-negative T cells and IL-17-producing cells in the lymph nodes, and produced less anti-DNA antibodies.⁴ These experiments indicate the importance of

aberrant activation of IL-23/IL-17 axis and IL-23R-mediated signaling in the development of LN.

Recently, Ooi et al⁵ demonstrated that mice deficient in IL-23 were protected from experimental autoimmune anti-GBM glomerulonephritis, but mice with IL-23 were not. IL-23-deficient strains also exhibited lower auto-antibody titers, reduced cellular reactivity, diminished production of cytokines such as interferon-gamma (Th1) and IL-17A (Th17), and less renal disease and glomerular IgG deposition. It shows that autoreactivity to the Goodpasture antigen, the non-collagenous domain of alpha3 type IV collagen [alpha3(IV)NC1], is directed primarily by IL-23, absence of which results in hyporeactivity including, but extending beyond a deficient Th17 response.

Therefore, it is possible that IL-23, a heterodimer composed of IL-12p40 and IL-23p19 subunits, and IL-17A, a cytokine produced by the IL-23-maintained Th17 subset, may play a pivotal role in the pathogenesis of coexisting LN and anti-GBM disease. However, further studies are necessary to elucidate the exact molecular role and signaling transduction pathway of IL-23 and IL-17 during the disease process. The relationship between LN and Goodpasture's syndrome and the proper biological treatment should also be further evaluated in the future.

Dr. Se Jin Park¹,
Dr. Ji Hong Kim²,
Dr. Tae Sun Ha³,
Dr. Jae Il Shin²

¹Department of Pediatrics, Ajou University School of Medicine, Ajou University Hospital, Suwon, ²Department of Pediatrics, Yonsei University College of Medicine, Severance Children's Hospital, ³Department of Pediatrics, Chungbuk National University College of Medicine, Cheongju, Korea
E-mail: shinji@yuhs.ac

3. Wong CK, Lit LC, Tam LS, Li EK, Wong PT, Lam CW. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: Implications for Th17-mediated inflammation in auto-immunity. *Clin Immunol* 2008;127: 85-93.
4. Kyttaris VC, Zhang Z, Kuchroo VK, Oukka M, Tsokos GC. Cutting edge: IL-23 receptor deficiency prevents the development of lupus nephritis in C57BL/6-lpr/lpr mice. *J Immunol* 2010;184:4605-9.
5. Ooi JD, Phoon RK, Holdsworth SR, Kitching AR. IL-23, not IL-12, directs autoimmunity to the Goodpasture antigen. *J Am Soc Nephrol* 2009;20:980-9.

References

1. Yadla M, Krishnakishore C, Reddy S, et al. An unusual association of anti-GBM diseases and lupus nephritis presenting as pulmonary renal syndrome. *Saudi J Kidney Dis Transpl* 2011; 22:349-51.
2. Zhang Z, Kyttaris VC, Tsokos GC. The role of IL-23/IL-17 axis in lupus nephritis. *J Immunol* 2009;183:3160-9.

